Blackstone Inc.

🇺🇸New York Stock Exchange
Back to all articles
Blackstone Inc. stock analysis BX overview
Somewhat Bullish +50

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?

📈 Blackstone Life Sciences committed $400 million to fund the development of Teva's autoimmune disease drug duvakitug.

💰 This major deal serves as a powerful endorsement of Teva's potential transition from a generic drug maker to an innovator.

🧬 The financed drug, duvakitug, is a monoclonal antibody targeting TL1A for treating ulcerative colitis and Crohn's disease.

📊 Teva and partner Sanofi showed positive Phase 2 results with durable efficacy over 44 weeks of treatment.

👩‍⚕️ Blackstone Life Sciences boasts an 86% success rate investing in Phase 3 drugs with a team of 20 healthcare experts.

🔬 Beyond duvakitug, Teva has two other late-stage medicines including an olanzapine injectable for schizophrenia.

🌬️ The company is also advancing TEV-248, a dual-action rescue inhaler for asthma in Phase 3 testing.

💉 Teva holds five biosimilar programs awaiting FDA approval for drugs like Eylea and Simponi.

📈 Credit rating agencies recognized Teva's improvement with S&P upgrading its rating to BB+ in December 2025.

🏆 Wall Street analysts are bullish, with 12 out of 13 survey participants rating the stock as "buy" or "strong buy."

💼 Blackstone stands to gain milestone payments and royalties from duvakitug sales, giving them skin in the game.

📉 Teva currently trades at a forward earnings multiple of only 11.5, presenting a case for it being a value stock.

⚠️ The Motley Fool advises risk-averse investors to avoid Teva while aggressive investors might find it appealing.

📉 The Motley Fool's Stock Advisor team excluded Teva from their list of top 10 stocks to buy right now.

📊 The article promotes investing in the Motley Fool's stock lists, which historically outperformed the S&P 500.

Bullish Signals
  • Blackstone committed $400 million to fund the development of Teva's promising autoimmune disease drug duvakitug, signaling strong confidence in its potential.
  • Duvakitug is currently being evaluated in Phase 3 clinical studies for ulcerative colitis and Crohn's disease, following positive Phase 2 results showing durable efficacy over 44 weeks.
  • Paris Panayiotopoulos of Blackstone Life Sciences stated that duvakitug has the potential to be a best-in-class therapy in a large and growing space.
  • Teva's pipeline includes two other innovative medicines in late-stage testing, including an olanzapine long-acting injectable for schizophrenia awaiting FDA approval and TEV-248 for asthma in Phase 3.
  • Credit rating agencies recognize Teva's turnaround, with S&P Global upgrading its credit rating to BB+ from BB in December 2025 with a stable outlook, and Moody's revising its outlook to positive from stable.
  • Wall Street sentiment is overwhelmingly bullish on the stock, with 12 out of 13 surveyed analysts rating Teva as a 'buy' or 'strong buy'.
  • Teva continues to lead in biosimilar development with five additional approvals awaiting FDA clearance for drugs like Eylea, Prolia, Simponi, and Xgeva.
  • The stock trades at a forward earnings multiple of only 11.5, presenting a compelling value proposition compared to other pharma peers.
Risk Factors
  • The Motley Fool Stock Advisor analyst team explicitly identified Teva Pharmaceutical Industries as not being among their top 10 recommended stocks to buy now.
  • Despite positive analyst coverage, one outlier out of 13 analysts surveyed by S&P Global in April recommended only holding the stock rather than buying or strongly buying it.
  • The $400 million commitment from Blackstone is contingent on duvakitug winning regulatory approval and succeeding commercially, introducing significant downside risk if Phase 3 studies fail or FDA approval is denied.
  • Teva's pipeline remains heavily reliant on multiple late-stage approvals including U.S. FDA approval for olanzapine long-acting injectable and five biosimilars, creating concentration risk if regulatory hurdles are not cleared.
  • Blackstone's involvement provides milestone payments rather than equity ownership in this specific deal, limiting the direct upside for Teva shareholders compared to an equity investment.
Full Analysis
Blackstone's Life Sciences division has committed $400 million to fund the development of duvakitug, an experimental monoclonal antibody targeting TL1A for treating autoimmune conditions like ulcerative colitis and Crohn's disease. This partnership marks a significant endorsement from a major alternative asset manager with a track record of 86% success in advancing phase 3 drugs, suggesting strong confidence in Teva Pharmaceutical Industries' transition from a generic drug maker to an innovative biopharmaceutical company. The investment includes milestone payments and royalties for Blackstone upon regulatory approval, indicating they have "skin in the game" regarding duvakitug's commercial potential. The deal highlights Teva's expanding pipeline beyond this flagship asset, which includes olanzapine long-acting injectable for schizophrenia awaiting FDA approval and TEV-248, a dual-action inhaler for asthma also in phase 3 testing. Additionally, Teva maintains a robust biosimilar portfolio with five products pending FDA approval. Credit rating agencies have responded positively to this turnaround; S&P Global upgraded Teva's credit rating to BB+ in December 2025, while Moody's revised its outlook to positive. Wall Street sentiment is similarly bullish, with 12 out of 13 analysts surveyed in April recommending the stock as a "buy" or "strong buy." Despite the optimistic fundamentals, the article concludes by noting the stock carries risk that may deter risk-averse investors, though aggressive investors might view the forward earnings multiple of 11.5 as indicative of value. The narrative is contextualized by Blackstone's involvement and the broader market perception that Teva is shedding its old image to become a leading biopharmaceutical innovator.